Colorado gets $5.5 million in EpiPen settlement
DENVER — Mylan, the pharmaceutical company that makes the EpiPen allergy treatment, is paying the state of Colorado $5.5 million.
The payment is part of a national settlement over claims it shorted money to Medicaid, the Denver Post reports. In total, it is paying $465 million to the federal government and to states.
The claims say that Mylan misclassified EpiPen as a generic drug while it was marketing EpiPen as a brand-name drug and raising prices 400 percent between 2010 and 2016. By classifying as generic, Mylan avoided paying rebates to state Medicaid programs, the claims said.
SPONSORED CONTENT
DENVER — Mylan, the pharmaceutical company that makes the EpiPen allergy treatment, is paying the state of Colorado $5.5 million.
The payment is part of a national settlement over claims it shorted money to Medicaid, the Denver Post reports. In total, it is paying $465 million to the federal government and to states.
The claims say that Mylan misclassified EpiPen as a generic drug while it was marketing EpiPen as a brand-name drug and raising prices 400 percent between 2010 and 2016. By classifying as generic, Mylan avoided paying rebates to state Medicaid programs, the claims said.